Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 591.5 g/mol |
|---|---|
| Molecular Formula | C12H17NO20S3-4 |
| XLogP3 | -5.6 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 21 |
| Rotatable Bond Count | 6 |
| Exact Mass | 590.95060545 g/mol |
| Monoisotopic Mass | 590.95060545 g/mol |
| Topological Polar Surface Area | 376 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | -4 |
| Complexity | 1040 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 6 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Heparin sodium in plastic container |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 2 of 4 | |
|---|---|
| Drug Name | Heparin sodium preservative free |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Heparin sodium in plastic container |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 5,000 units/ml; 20,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Fresenius Kabi Usa |
| 4 of 4 | |
|---|---|
| Drug Name | Heparin sodium preservative free |
| Active Ingredient | Heparin sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10,000 units/ml; 1,000 units/ml |
| Market Status | Prescription |
| Company | Hospira; Shenzhen Techdow; Pfizer; Fresenius Kabi Usa; Sagent Pharms |
Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 23, 2022

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2022

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Leo Pharma | Sunnybrook Research Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2021

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Leo Pharma | Sunnybrook Research Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2021

Details:
Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Innohep
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 20, 2015

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2015

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2014

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Christine Ribic
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Christine Ribic
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Tinzaparin for Anticoagulation in Hemodialysis
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Nephrology Brand Name: Fragmin
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use Of Fragmin In Hemodialysis
Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Fragmin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2013

Details:
Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Lead Product(s): Dalteparin sodium,Enoxaparin Sodium,Tedelparin
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 11, 2013

Lead Product(s) : Dalteparin sodium,Enoxaparin Sodium,Tedelparin
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2013

Details:
Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Aarhus University Hospital | Leo Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2011

Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Aarhus University Hospital | Leo Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.
Lead Product(s): Dalteparin sodium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Innohep
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dalteparin sodium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Veno...
Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.
Product Name : Innohep
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine Forte
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 28-11-2000
Application Number : 63496
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 01-04-1998
Application Number : 61783
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine Forte
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 28-11-2000
Application Number : 63498
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 01-06-1991
Application Number : 58983
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 01-11-1989
Application Number : 58496
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine Forte
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 28-11-2000
Application Number : 63497
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine
Dosage Form : Injectable Solution
Dosage Strength :
Packaging :
Approval Date : 01-06-1991
Application Number : 58982
Regulatory Info : Cancelled
Registration Country : Spain
Regulatory Info : Cancelled
Registration Country : Spain
Brand Name : Fraxiparine
Dosage Form : Injectable Solution
Dosage Strength : 9500IU
Packaging :
Approval Date : 02-06-2021
Application Number : 86000
Regulatory Info : Cancelled
Registration Country : Spain
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Fraxiparine 0.8ml
Dosage Form : INJ
Dosage Strength : 7600iu/0.8ml
Packaging : 0.8X10iu/0.8ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Fraxiparine 1.0ml
Dosage Form : INJ
Dosage Strength : 9500iu/1ml
Packaging : 1X10iu/1ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
38
PharmaCompass offers a list of Dalteparin sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dalteparin sodium manufacturer or Dalteparin sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dalteparin sodium manufacturer or Dalteparin sodium supplier.
PharmaCompass also assists you with knowing the Dalteparin sodium API Price utilized in the formulation of products. Dalteparin sodium API Price is not always fixed or binding as the Dalteparin sodium Price is obtained through a variety of data sources. The Dalteparin sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Heparinum natricum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Heparinum natricum, including repackagers and relabelers. The FDA regulates Heparinum natricum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Heparinum natricum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Heparinum natricum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Heparinum natricum supplier is an individual or a company that provides Heparinum natricum active pharmaceutical ingredient (API) or Heparinum natricum finished formulations upon request. The Heparinum natricum suppliers may include Heparinum natricum API manufacturers, exporters, distributors and traders.
click here to find a list of Heparinum natricum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Heparinum natricum DMF (Drug Master File) is a document detailing the whole manufacturing process of Heparinum natricum active pharmaceutical ingredient (API) in detail. Different forms of Heparinum natricum DMFs exist exist since differing nations have different regulations, such as Heparinum natricum USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Heparinum natricum DMF submitted to regulatory agencies in the US is known as a USDMF. Heparinum natricum USDMF includes data on Heparinum natricum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Heparinum natricum USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Heparinum natricum suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Heparinum natricum Drug Master File in Japan (Heparinum natricum JDMF) empowers Heparinum natricum API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Heparinum natricum JDMF during the approval evaluation for pharmaceutical products. At the time of Heparinum natricum JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Heparinum natricum suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Heparinum natricum Drug Master File in Korea (Heparinum natricum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Heparinum natricum. The MFDS reviews the Heparinum natricum KDMF as part of the drug registration process and uses the information provided in the Heparinum natricum KDMF to evaluate the safety and efficacy of the drug.
After submitting a Heparinum natricum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Heparinum natricum API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Heparinum natricum suppliers with KDMF on PharmaCompass.
Heparinum natricum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Heparinum natricum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Heparinum natricum GMP manufacturer or Heparinum natricum GMP API supplier for your needs.
A Heparinum natricum CoA (Certificate of Analysis) is a formal document that attests to Heparinum natricum's compliance with Heparinum natricum specifications and serves as a tool for batch-level quality control.
Heparinum natricum CoA mostly includes findings from lab analyses of a specific batch. For each Heparinum natricum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Heparinum natricum may be tested according to a variety of international standards, such as European Pharmacopoeia (Heparinum natricum EP), Heparinum natricum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Heparinum natricum USP).